NASDAQ:CORT Corcept Therapeutics (CORT) Stock Forecast, Price & News $27.55 -5.44 (-16.49%) (As of 01:40 PM ET) Add Compare Share Share Today's Range$25.15▼$32.7450-Day Range$23.84▼$33.8052-Week Range$17.86▼$34.28Volume3.55 million shsAverage Volume720,073 shsMarket Capitalization$2.83 billionP/E Ratio33.19Dividend YieldN/APrice Target$30.81 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Corcept Therapeutics MarketRank™ ForecastAnalyst RatingHold2.43 Rating ScoreUpside/Downside18.5% Upside$30.81 Price TargetShort InterestBearish16.58% of Float Sold ShortDividend StrengthN/ASustainability-0.96Upright™ Environmental ScoreNews Sentiment0.80Based on 11 Articles This WeekInsider TradingSelling Shares$2.75 M Sold Last QuarterProj. Earnings Growth6.41%From $0.78 to $0.83 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 starsMedical Sector715th out of 970 stocksPharmaceutical Preparations Industry343rd out of 456 stocks 2.2 Analyst's Opinion Consensus RatingCorcept Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.81, Corcept Therapeutics has a forecasted upside of 18.5% from its current price of $26.00.Amount of Analyst CoverageCorcept Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.58% of the float of Corcept Therapeutics has been sold short.Short Interest Ratio / Days to CoverCorcept Therapeutics has a short interest ratio ("days to cover") of 24.1, which indicates bearish sentiment.Change versus previous monthShort interest in Corcept Therapeutics has recently decreased by 2.16%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCorcept Therapeutics does not currently pay a dividend.Dividend GrowthCorcept Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorcept Therapeutics has received a 62.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sex hormones and modulators of the genital system (G03)", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Corcept Therapeutics is -0.96. Previous Next 3.2 News and Social Media Coverage News SentimentCorcept Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Corcept Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for CORT on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows4 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,746,228.00 in company stock.Percentage Held by Insiders19.80% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.80% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Corcept Therapeutics are expected to grow by 6.41% in the coming year, from $0.78 to $0.83 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corcept Therapeutics is 31.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.42.Price to Earnings Ratio vs. SectorThe P/E ratio of Corcept Therapeutics is 31.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 98.39.Price to Book Value per Share RatioCorcept Therapeutics has a P/B Ratio of 5.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Corcept Therapeutics (NASDAQ:CORT) StockCorcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Read More CORT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CORT Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Receives $30.81 Consensus Price Target from AnalystsSeptember 28, 2023 | finance.yahoo.comViatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal AgentSeptember 29, 2023 | UNKNOWN (Ad)The Next Best AI Stock to Watch After NvidiaThis emerging NASDAQ company may be the best AI stock to watch in the AI boom. September 26, 2023 | finance.yahoo.comNovo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease DrugsSeptember 25, 2023 | stocknews.comInvestors Keeping a Close Eye on These 3 Biotech StocksSeptember 23, 2023 | americanbankingnews.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $812,000.00 in StockSeptember 23, 2023 | americanbankingnews.comInsider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $812,000.00 in StockSeptember 22, 2023 | finance.yahoo.comMoleculin (MBRX) Posts Update From Lung Cancer Study, Stock UpSeptember 29, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 22, 2023 | americanbankingnews.comQ2 2024 EPS Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT) Lifted by Zacks ResearchSeptember 21, 2023 | benzinga.comMassive Insider Trade At Corcept TherapeuticsSeptember 19, 2023 | finance.yahoo.comStrength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength?September 12, 2023 | finance.yahoo.comAquestive's (AQST) Libervant Accepted for FDA Review, Stock UpSeptember 7, 2023 | finance.yahoo.comDecoding Corcept Therapeutics (CORT)'s Market Value: An In-Depth AnalysisSeptember 7, 2023 | finance.yahoo.comCorcept Therapeutics Inc's Meteoric Rise: Unpacking the 36% Surge in Just 3 MonthsSeptember 6, 2023 | finance.yahoo.comTheravance Bio (TBPH) Down 2.3% Since Last Earnings Report: Can It Rebound?September 1, 2023 | finance.yahoo.comWhy Is Corcept (CORT) Up 4.8% Since Last Earnings Report?August 30, 2023 | stocknews.comUnlocking Biotech's Potential With 3 Stocks to BuyAugust 29, 2023 | finance.yahoo.comHas Compugen (CGEN) Outpaced Other Medical Stocks This Year?August 26, 2023 | msn.comCorcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade)August 25, 2023 | msn.comCanaccord Genuity Maintains Corcept Therapeutics (CORT) Buy RecommendationAugust 25, 2023 | markets.businessinsider.comExpert Ratings for Corcept TherapeuticsAugust 25, 2023 | finance.yahoo.comHere's Why You Should Add Corcept (CORT) Stock to Your PortfolioAugust 25, 2023 | finance.yahoo.comNovo Nordisk (NVO) Posts Upbeat Data From Heart Failure StudyAugust 21, 2023 | finance.yahoo.comBelite Bio (BLTE) Stock Surges 72% in a Month: Here's WhyAugust 14, 2023 | stocknews.comWhich Stock Do Investors Consider a Heathier Investment: Bionano Genomics (BNGO) vs. Corcept Therapeutics (CORT)August 10, 2023 | finance.yahoo.comJazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 ViewSee More Headlines Receive CORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CORT Company Calendar Last Earnings8/02/2023Today9/29/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:CORT CUSIP21835210 CIK1088856 Webwww.corcept.com Phone(650) 327-3270Fax650-327-3218Employees299Year Founded1998Price Target and Rating Average Stock Price Forecast$30.81 High Stock Price Forecast$47.50 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+11.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$0.83 Trailing P/E Ratio33.19 Forward P/E Ratio35.32 P/E GrowthN/ANet Income$101.42 million Net Margins22.02% Pretax Margin25.38% Return on Equity19.57% Return on Assets16.69% Debt Debt-to-Equity RatioN/A Current Ratio4.65 Quick Ratio4.57 Sales & Book Value Annual Sales$401.86 million Price / Sales7.03 Cash Flow$0.82 per share Price / Cash Flow33.42 Book Value$4.66 per share Price / Book5.91Miscellaneous Outstanding Shares102,550,000Free Float82,243,000Market Cap$2.83 billion OptionableOptionable Beta0.45 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Joseph K. Belanoff M.D. (Age 66)Co-Founder, Pres, CEO & Director Comp: $1.82MMr. Atabak Mokari (Age 46)CFO & Treasurer Comp: $760.75kDr. Hazel Hunt Ph.D. (Age 63)Chief Scientific Officer Comp: $895.16kMr. Sean Maduck (Age 46)Pres of Corcept Endocrinology Comp: $823.42kMr. Gary Charles Robb (Age 60)Chief Bus. Officer & Sec. Comp: $963kMr. Joseph Douglas Lyon (Age 44)Chief Accounting Officer Ms. Amy FloodChief HR & Communications OfficerDr. William Guyer Pharm.D. (Age 55)Chief Devel. Officer More ExecutivesKey CompetitorsPerrigoNYSE:PRGOSupernus PharmaceuticalsNASDAQ:SUPNPacira BioSciencesNASDAQ:PCRXJazz PharmaceuticalsNASDAQ:JAZZAxsome TherapeuticsNASDAQ:AXSMView All CompetitorsInsiders & InstitutionsSean MaduckSold 25,000 sharesTotal: $812,000.00 ($32.48/share)Bluefin Capital Management LLCSold 20,000 shares on 9/11/2023Ownership: 0.000%Daniel N. Swisher, Jr.Sold 2,200 sharesTotal: $72,380.00 ($32.90/share)Joseph Douglas LyonSold 5,000 sharesTotal: $163,650.00 ($32.73/share)Daniel N. Swisher, Jr.Sold 1,550 sharesTotal: $50,731.50 ($32.73/share)View All Insider TransactionsView All Institutional Transactions CORT Stock - Frequently Asked Questions Should I buy or sell Corcept Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CORT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CORT, but not buy additional shares or sell existing shares. View CORT analyst ratings or view top-rated stocks. What is Corcept Therapeutics' stock price forecast for 2023? 7 equities research analysts have issued 12-month price targets for Corcept Therapeutics' stock. Their CORT share price forecasts range from $22.00 to $47.50. On average, they expect the company's stock price to reach $30.81 in the next twelve months. This suggests a possible upside of 11.8% from the stock's current price. View analysts price targets for CORT or view top-rated stocks among Wall Street analysts. How have CORT shares performed in 2023? Corcept Therapeutics' stock was trading at $20.31 on January 1st, 2023. Since then, CORT shares have increased by 35.6% and is now trading at $27.55. View the best growth stocks for 2023 here. When is Corcept Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our CORT earnings forecast. How were Corcept Therapeutics' earnings last quarter? Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.10. The biotechnology company had revenue of $117.72 million for the quarter, compared to the consensus estimate of $109.60 million. Corcept Therapeutics had a trailing twelve-month return on equity of 19.57% and a net margin of 22.02%. The company's quarterly revenue was up 13.9% on a year-over-year basis. During the same period last year, the company earned $0.24 earnings per share. What ETFs hold Corcept Therapeutics' stock? ETFs with the largest weight of Corcept Therapeutics (NASDAQ:CORT) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Hartford Multifactor Small Cap ETF (ROSC) and Distillate Small/Mid Cash Flow ETF (DSMC). What guidance has Corcept Therapeutics issued on next quarter's earnings? Corcept Therapeutics issued an update on its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $455.00 million-$470.00 million, compared to the consensus revenue estimate of $443.89 million. What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO? 6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Corcept Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI). What is Corcept Therapeutics' stock symbol? Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT." How do I buy shares of Corcept Therapeutics? Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Corcept Therapeutics' stock price today? One share of CORT stock can currently be purchased for approximately $27.55. How much money does Corcept Therapeutics make? Corcept Therapeutics (NASDAQ:CORT) has a market capitalization of $2.83 billion and generates $401.86 million in revenue each year. The biotechnology company earns $101.42 million in net income (profit) each year or $0.83 on an earnings per share basis. How many employees does Corcept Therapeutics have? The company employs 299 workers across the globe. How can I contact Corcept Therapeutics? Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The official website for the company is www.corcept.com. The biotechnology company can be reached via phone at (650) 327-3270, via email at cjames@corcept.com, or via fax at 650-327-3218. This page (NASDAQ:CORT) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.